Drug Trial Radar · NCT04878003
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Last checked: Nov 19, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
52
Planned (sponsor's estimate)
Start
Apr 13, 2021
Primary completion
May 2024
Study completion Oct 2025
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.
Conditions
- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
- Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Interventions
KRT-232Drug
KRT-232, administration by mouth
TL-895Drug
TL-895, administration by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen Volume Reduction (SVR)Time frame: 24 weeks
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
Innovative Clinical Research Institute
Glendale, California · Recruiting
Innovative Clinical Research Institute
Whittier, California · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Republican Scientific Practical Center of Radiation Medicine and Human Ecology
Belarus’, Belarus · Recruiting
Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology
Minsk, Belarus · Recruiting
UMHAT Georgi Stranski
Pleven, Bulgaria · Recruiting
Medical Centre Hipokrat N
Plovdiv, Bulgaria · Recruiting
UMHAT Sv. Ivan Rilski EAD
Sofia, Bulgaria · Recruiting
Military Medical Academy
Sofia, Bulgaria · Recruiting
Specialized Hospital for Active Treatment of Hematologic Diseases
Sofia, Bulgaria · Recruiting
JSC EVEX Hospitals
Kutaisi, Georgia · Recruiting
LTD M.Zodelava Hematology Centre
Tbilisi, Georgia · Recruiting
K.Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia · Recruiting
Centro de Investigacion Medica Aquascalientes (CIMA)
Aguascalientes, Mexico · Recruiting
Unidad de Investigacion CIMA SC
Chihuahua City, Mexico · Recruiting
Centro de Investigacion Clinica de Oaxaca (CICLO)
Oaxaca City, Mexico · Recruiting
Sociedad de Metabolismo Y Corazon - SOMECO
Veracruz, Mexico · Recruiting
Samodzielny Publiczny Zakład Opieki Zdrowotnej Zespół Szpitali Miejskich
Katowice, Poland · Recruiting
Szpital Wojewodzki w Opolu Sp. z o.o., Oddzial Hematologii i Onkologii Hematologicznej
Opole, Poland · Recruiting
Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o.
Słupsk, Poland · Recruiting
Botkin City Clinical Hospital
Moscow, Russia · Recruiting
Republican Hospital n.a. V.A. Baranov
Petrozavodsk, Russia · Recruiting
Pavlov First Saint Petersburg State Medical University
Saint Petersburg, Russia · Recruiting
Almazov National Medical Research Center
Saint Petersburg, Russia · Recruiting
Almazov National Medical Research Centre
Saint Petersburg, Russia · Recruiting
Samara State Medical University
Samara, Russia · Recruiting
Wits Baragwanath Clinical Hematology Department
Soweto, South Africa · Recruiting
City Hematology Center of Municipal Non-Profit Enterprise City Clinical Hospital #4 of Dnipro City Council
Dnipro, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.